CRON · XBRL financial data

Cronos Group financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRON's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	47	74	92	87	118	147
Gross profit	(26)	(18)	12	12	25	63
Research and development	20	23	13	6	4	4
General and administrative	81	96	71	49	47	42
Total operating expenses	154	543	137	97	102	80
Operating income (loss)	(179)	(561)	(125)	(85)	(77)	(17)
Interest income	19	9	23	—	—	—
Interest expense	0	0	0	—	—	—
Other income (expense)	(2)	1	(0)	1	(0)	(0)
Income tax expense (benefit)	1	(0)	34	(3)	(3)	(14)
Net income (loss)	(73)	(396)	(169)	(74)	41	(9)
Earnings per share, basic USD per share	(0.21)	(1.07)	(0.45)	(0.19)	0.11	(0.02)
Earnings per share, diluted USD per share	(0.21)	(1.07)	(0.45)	(0.19)	0.11	(0.02)
Weighted average shares, basic millions of shares	352	370	377	381	382	383
Weighted average shares, diluted millions of shares	352	370	377	381	386	383

Fiscal years (CRON's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,078	887	765	669	859	792
Short-term investments	212	118	113	192	0	40
Accounts receivable	9	22	23	14	15	34
Inventory	44	33	38	30	33	47
Prepaid and other current assets	11	9	7	5	6	8
Total current assets	1,372	1,080	960	933	936	944
Property and equipment, net	188	74	61	59	133	146
Right-of-use asset	10	9	2	1	1	1
Goodwill	180	1	1	1	63	66
Total assets	1,926	1,398	1,213	1,140	1,166	1,197
Accounts payable	12	11	11	12	17	12
Accrued liabilities	23	26	22	28	32	36
Total current liabilities	207	54	68	41	50	48
Lease liability, non-current	8	7	3	2	1	1
Total liabilities	218	63	72	44	55	54
Retained earnings	1,065	659	491	417	458	448
Total stockholders' equity	1,711	1,337	1,144	1,100	1,064	1,094
Total liabilities and equity	1,926	1,398	1,213	1,140	1,166	1,197
Common shares outstanding (cover page) millions of shares	360	375	381	381	383	379

Fiscal years (CRON's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(73)	(396)	(169)	(74)	41	(9)
Stock-based compensation	15	10	15	9	9	7
Depreciation and amortization	7	15	13	8	9	14
Net cash from operating activities	(142)	(154)	(89)	(43)	19	26
Purchases of property and equipment	31	11	3	3	12	26
Net cash from investing activities	20	(29)	(2)	(59)	175	(77)
Share repurchases	—	—	—	0	0	10
Net cash from financing activities	(5)	(13)	(3)	(1)	(1)	(20)
Net change in cash	(122)	(191)	(122)	(95)	190	(67)

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Cronos Group	467	53	24*	368.4M	—	Q2 FY26 10-QJun 30, 2026
REGENXBIO	36	108	(62)*	66.0M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
CytomX Therapeutics	17	1.4	(18)*	217.9M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Oruka Therapeutics	268	not reported	(33)*	66.2M	26.4 quarters	Q2 FY26 10-QJun 30, 2026
Capricor Therapeutics	21	not reported	(31)*	58.1M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Cryoport	269	49	1.1*	50.6M	—	Q2 FY26 10-QJun 30, 2026
CytoDyn	16	not reported	(7.7)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.